Clinical Trials · NCT07027124
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Enrollment
- 40
- Start date
- May 2026
- Locations
- 1 site, United States
- Primary endpoint
- Proportion of patients who achieve Minimal residual disease (MRD)